Figure S1 from The <i>MCT4</i> Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer

Candidate MCT4-targeting ASOs are able to inhibit cell proliferation and MCT4 expression of LNCaP human prostate cancer cells 48 hours after transfection. A) MCT4 ASOs are able to inhibit LNCaP cell proliferation to levels comparable to those observed with other human prostate cancer cell lines. B) The decrease in cell proliferation is associated with a decrease in MCT4 expression. Taken together, the data suggest that the inhibitory effect of MCT4 ASOs may be more associated with a glycolytic phenotype than with androgen receptor status.</p

Table S1 from The <i>MCT4</i> Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer

List of Antisense Oligonucleotides (ASOs) and qPCR Primer Sequences used.</p

Figure S2 from The <i>MCT4</i> Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer

Candidate MCT4 ASOs are able to inhibit PC-3 cell migration and tissue invasion in vitro. A) Treatment of PC3 cells with candidate MCT4 ASOs resulted in an inhibition of cell migration through a transwell, as indicated by a reduction in the number of migrated cells observed. B) Treatment with MCT4 ASO also inhibited the ability of PC-3 cells to invade Matrigel. As such, MCT4-mediated lactic acid secretion could play an important role in cancer metastasis.</p

Figure S3 from The <i>MCT4</i> Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer

Treatment of nude mice with MCT4 ASO did not cause host toxicity as measured by animal weights. A) Animal weights were monitored throughout the duration of the in vivo study, and treatment with MCT4 ASOs did not significantly affect the average animal weight of each group. B) The individual animal weights also remained stable throughout the treatment period.</p

Table S2 from The <i>MCT4</i> Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer

Additional Clinicopathological Characteristics associated with high MCT4 expression in patient samples.</p

Supplementary Table S1 from Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

Patient Identification</p

Supplementary Table S2 from Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

List of patient fusions</p

Supplementary Table S4 from Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

List of patient epitopes</p

Supplementary Table S3 from Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

List of patient CASQ</p

Supplementary Table S1 from <i>BIRC6</i> Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

The qPCR primer sequences used</p